+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Anorexia-Cachexia Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 148 Pages
  • May 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5602699
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Drugs In Development, 2022, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape.

Cancer anorexia-cachexia syndrome is defined as progressive weight loss associated with malignancy and is characterized by loss of appetite (anorexia), skeletal muscle wasting, and reduced adipose tissue. Approximately 50% of cancer patients report abnormalities of eating behavior at the time of first diagnosis and prevalence is even higher at approximately 65%. The incidence of weight loss upon diagnosis varies greatly according to the tumor site.

Report Highlights


The publisher's latest pipeline guide Cancer Anorexia-Cachexia Syndrome - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 5, 2, 1, 15 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Report Coverage
Cancer Anorexia-Cachexia Syndrome - Overview
Cancer Anorexia-Cachexia Syndrome - Therapeutics Development

Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Cancer Anorexia-Cachexia Syndrome - Therapeutics Assessment

Assesement by Target

Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cancer Anorexia-Cachexia Syndrome - Companies Involved in Therapeutics Development
Cancer Anorexia-Cachexia Syndrome - Drug Profiles
Cancer Anorexia-Cachexia Syndrome - Dormant Projects
Cancer Anorexia-Cachexia Syndrome - Discontinued Products
Cancer Anorexia-Cachexia Syndrome - Product Development Milestones

Featured News

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables
  • Number of - Products under Development for Cancer Anorexia-Cachexia Syndrome, 2022
  • Number of - Products under Development by Companies, 2022
  • Number of - Products under Development by Companies, 2022 (Contd..1)
  • Number of - Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Companies, 2022 (Contd..1)
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
Cancer Anorexia-Cachexia Syndrome - Dormant Projects, 2022
Cancer Anorexia-Cachexia Syndrome - Dormant Projects, 2022 (Contd..1)
Cancer Anorexia-Cachexia Syndrome - Dormant Projects, 2022 (Contd..2)
Cancer Anorexia-Cachexia Syndrome - Discontinued Products, 2022

List of Figures
  • Number of - Products under Development for Cancer Anorexia-Cachexia Syndrome, 2022
  • Number of - Products under Development by Companies, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AAVogen Inc
  • Abreos Biosciences Inc
  • Actimed Therapeutics Ltd
  • Aeterna Zentaris Inc
  • Aphios Corp
  • Artelo Biosciences Inc
  • AtoGen Co Ltd
  • AVEO Pharmaceuticals Inc
  • Betula Pharma
  • Byomass Inc
  • Cannabics Pharmaceuticals Inc
  • Creative